- Home
- CRGX vs INMB Comparison
CRGX vs INMB Comparison
Compare CRGX & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- INMB
- Stock Information
- Founded
- CRGX 2021
- INMB 2015
- Country
- CRGX United States
- INMB United States
- Employees
- CRGX N/A
- INMB N/A
- Industry
- CRGX
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- CRGX
- INMB Health Care
- Exchange
- CRGX Nasdaq
- INMB Nasdaq
- Market Cap
- CRGX 213.5M
- INMB 176.5M
- IPO Year
- CRGX 2023
- INMB 2019
- Fundamental
- Price
- CRGX $4.02
- INMB $6.97
- Analyst Decision
- CRGX Hold
- INMB Strong Buy
- Analyst Count
- CRGX 7
- INMB 3
- Target Price
- CRGX $4.67
- INMB $24.33
- AVG Volume (30 Days)
- CRGX 763.5K
- INMB 215.6K
- Earning Date
- CRGX 05-16-2025
- INMB 05-08-2025
- Dividend Yield
- CRGX N/A
- INMB N/A
- EPS Growth
- CRGX N/A
- INMB N/A
- EPS
- CRGX N/A
- INMB N/A
- Revenue
- CRGX N/A
- INMB $50,000.00
- Revenue This Year
- CRGX $58.18
- INMB N/A
- Revenue Next Year
- CRGX N/A
- INMB N/A
- P/E Ratio
- CRGX N/A
- INMB N/A
- Revenue Growth
- CRGX N/A
- INMB N/A
- 52 Week Low
- CRGX $3.00
- INMB $4.32
- 52 Week High
- CRGX $25.45
- INMB $11.76
- Technical
- Relative Strength Index (RSI)
- CRGX 37.02
- INMB 40.42
- Support Level
- CRGX $3.97
- INMB $6.98
- Resistance Level
- CRGX $4.66
- INMB $8.00
- Average True Range (ATR)
- CRGX 0.20
- INMB 0.49
- MACD
- CRGX -0.05
- INMB -0.07
- Stochastic Oscillator
- CRGX 6.25
- INMB 6.59
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.